Bayer has agreed to pay about $10.5 billion to settle claims in the U.S. that its weedkiller Roundup led to cancer in nearly 100,000 patients exposed to the popular herbicide, according to a law firm representing some of the plaintiffs.
What happened: This sweeping agreement is the first settlement to be reached among the flood of lawsuits filed against the company from people with non-Hodgkins lymphoma. It comes after the World Health Organizations cancer research arm concluded in 2015 that glyphosate, the key ingredient in Roundup, is a probable carcinogen.
Bayer has lost multiple million-dollar cases over glyphosate claims. Thousands of plaintiffs have filed lawsuits across the country against Bayer, which inherited Monsantos products after it purchased the company.
Up to $9.5 billion will be paid to settle most of the pending litigation, Bayer said. The settlement also sets aside $1.25 billion to resolve potential future claims and resRead More – Source
Bayer has agreed to pay about $10.5 billion to settle claims in the U.S. that its weedkiller Roundup led to cancer in nearly 100,000 patients exposed to the popular herbicide, according to a law firm representing some of the plaintiffs.
What happened: This sweeping agreement is the first settlement to be reached among the flood of lawsuits filed against the company from people with non-Hodgkins lymphoma. It comes after the World Health Organizations cancer research arm concluded in 2015 that glyphosate, the key ingredient in Roundup, is a probable carcinogen.
Bayer has lost multiple million-dollar cases over glyphosate claims. Thousands of plaintiffs have filed lawsuits across the country against Bayer, which inherited Monsantos products after it purchased the company.
Up to $9.5 billion will be paid to settle most of the pending litigation, Bayer said. The settlement also sets aside $1.25 billion to resolve potential future claims and resRead More – Source
